Informations:
Erreur:
ID
45808
Description
Principal Investigator: Matthew Goetz, MD, Mayo Clinic, Rochester, MN, USA MeSH: Breast Neoplasms,Carcinoma, Ductal, Breast https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001050 The Breast Cancer Genome Guided Therapy Study (BEAUTY) is a prospective neoadjuvant clinical study enrolling 140 women with Stage I-III breast cancer. The goals of this study were to 1) perform comprehensive sequencing of germline and tumor tissues (exome and RNA seq), 2) identify genomic alterations and perturbed pathways associated with response/resistance to standard chemotherapy, and 3) develop patient-derived xenograft (PDX) for testing of therapeutic regimens chosen on the basis of alterations identified by genetic sequencing.
Lien
Mots-clés
Versions (1)
- 23/06/2023 23/06/2023 - Simon Heim
Détendeur de droits
Matthew Goetz, MD, Mayo Clinic, Rochester, MN, USA
Téléchargé le
23 juin 2023
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs001050 Breast Cancer Genome Guided Therapy Study (BEAUTY)
This subject phenotype table contains subject ID, pathological complete response in breast and nodes, clinical molecular tumor type, tumor stage, nodal stage, lab estimate of tumor percentage at baseline, Ki67 sensitivity, estrogen and progesterone receptor level, HER2 results by IHC or Fish, and patient age.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, and case control status of the subject. All subjects are patients with Stage I-III breast cancer.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject ID, pathological complete response in breast and nodes, clinical molecular tumor type, tumor stage, nodal stage, lab estimate of tumor percentage at baseline, Ki67 sensitivity, estrogen and progesterone receptor level, HER2 results by IHC or Fish, and patient age.
- This sample attributes table contains sample ID, body site where sample was collected, analyte type, tumor status, histologic type, primary metastatic tumor, primary tumor location, tumor stage, grade, treatment, name of the center which conducted sequencing, portion of sequencing lane, and comments.
Similar models
This subject phenotype table contains subject ID, pathological complete response in breast and nodes, clinical molecular tumor type, tumor stage, nodal stage, lab estimate of tumor percentage at baseline, Ki67 sensitivity, estrogen and progesterone receptor level, HER2 results by IHC or Fish, and patient age.
- StudyEvent: SEV1
- Eligibility Criteria
- The subject consent file includes subject IDs, consent information, and case control status of the subject. All subjects are patients with Stage I-III breast cancer.
- This data table contains a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs. The data table also includes sample aliases and sample use.
- This subject phenotype table contains subject ID, pathological complete response in breast and nodes, clinical molecular tumor type, tumor stage, nodal stage, lab estimate of tumor percentage at baseline, Ki67 sensitivity, estrogen and progesterone receptor level, HER2 results by IHC or Fish, and patient age.
- This sample attributes table contains sample ID, body site where sample was collected, analyte type, tumor status, histologic type, primary metastatic tumor, primary tumor location, tumor stage, grade, treatment, name of the center which conducted sequencing, portion of sequencing lane, and comments.
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Subject_ID
Item
Subject ID
string
C2348585 (UMLS CUI [1,1])
Breast.Nodal.CR.all
Item
Pathological complete response in breast and nodes (path-CR) after 24 weeks of chemo-therapy or the patient's regimen.
string
C0807321 (UMLS CUI [1,1])
C4318559 (UMLS CUI [1,2])
C4296167 (UMLS CUI [1,3])
C0006141 (UMLS CUI [1,4])
C4318559 (UMLS CUI [1,2])
C4296167 (UMLS CUI [1,3])
C0006141 (UMLS CUI [1,4])
Clinical.Molecular.Subtype
Item
Clinical molecular tumor type, based on baseline Ki67 results, estrogen receptor level and HER2 status (by IHC or FISH)
string
C0205210 (UMLS CUI [1,1])
C4263544 (UMLS CUI [1,2])
C1521991 (UMLS CUI [1,3])
C4049944 (UMLS CUI [1,4])
C0034804 (UMLS CUI [1,5])
C1512413 (UMLS CUI [1,6])
C0021044 (UMLS CUI [1,7])
C0162789 (UMLS CUI [1,8])
C4263544 (UMLS CUI [1,2])
C1521991 (UMLS CUI [1,3])
C4049944 (UMLS CUI [1,4])
C0034804 (UMLS CUI [1,5])
C1512413 (UMLS CUI [1,6])
C0021044 (UMLS CUI [1,7])
C0162789 (UMLS CUI [1,8])
T.stage
Item
Tumor stage, based on size and spread to skin or chest wall under breast
string
C1300072 (UMLS CUI [1,1])
C0456389 (UMLS CUI [1,2])
C0347065 (UMLS CUI [1,3])
C1123023 (UMLS CUI [1,4])
C0205076 (UMLS CUI [1,5])
C0456389 (UMLS CUI [1,2])
C0347065 (UMLS CUI [1,3])
C1123023 (UMLS CUI [1,4])
C0205076 (UMLS CUI [1,5])
N.stage
Item
Nodal stage, based on if tumor spread to lymph nodes by breast and, if so, how many nodes are affected
string
C0456532 (UMLS CUI [1,1])
Percentage.tumor.cells.baseline
Item
Lab estimate of tumor percentage at baseline
text
C0750572 (UMLS CUI [1,1])
C5237816 (UMLS CUI [1,2])
C1254595 (UMLS CUI [1,3])
C5237816 (UMLS CUI [1,2])
C1254595 (UMLS CUI [1,3])
Ki67Sensitivity
Item
Was tumor sensitive to chemo decreasing significantly by Ki67 measure?
string
C0006826 (UMLS CUI [1,1])
C0475276 (UMLS CUI [1,2])
C3854147 (UMLS CUI [1,3])
C4049944 (UMLS CUI [1,4])
C0475276 (UMLS CUI [1,2])
C3854147 (UMLS CUI [1,3])
C4049944 (UMLS CUI [1,4])
Estrogen.receptor
Item
Estrogen Receptor level
string
C2919271 (UMLS CUI [1,1])
Progesterone.receptor
Item
Progesterone Receptor level
string
C2919590 (UMLS CUI [1,1])
HER2.IHC
Item
HER2 results by IHC
string
C1512413 (UMLS CUI [1,1])
C0021044 (UMLS CUI [1,2])
C0021044 (UMLS CUI [1,2])
HER2.FISH
Item
HER2 results by Fish
string
C0162789 (UMLS CUI [1,1])
C1512413 (UMLS CUI [1,2])
C1512413 (UMLS CUI [1,2])
Age.group
Item
Patient age at date on study, marked in 10 year group
string
C0001779 (UMLS CUI [1,1])
C2348558 (UMLS CUI [1,2])
C2348558 (UMLS CUI [1,2])
Aucun commentaire